Akèy › Kansè poumon › Kalifòni › San Francisco
Etid klinik pou Kansè poumon nan San Francisco, CA
22 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of ZW251 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Kaiser Permanente-San Francisco, San Francisco
Smoking Cessation CM for Veterans With or at Risk for Cancer
Ap rekriteVolontè an sante akeyi
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Kaiser Permanente-San Francisco, San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- UCSF Medical Center-Mission Bay, San Francisco
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- California Pacific Medical Center-Pacific Campus, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, San Francisco
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Arlington, VA41 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Baltimore, MD40 etid
- Nashville, TN40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè ovè19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
- Gliyoblastòm17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.